STOCK TITAN

Madrigal Pharmaceuticals Inc - MDGL STOCK NEWS

Welcome to our dedicated news page for Madrigal Pharmaceuticals (Ticker: MDGL), a resource for investors and traders seeking the latest updates and insights on Madrigal Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Madrigal Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Madrigal Pharmaceuticals's position in the market.

Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced the publication of the pivotal Phase 3 MAESTRO-NASH trial of resmetirom in the New England Journal of Medicine. Resmetirom is the first investigational medicine for NASH to achieve fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial. It has the potential to become the first and only medicine approved for NASH, with a PDUFA date of March 14, 2024. The FDA granted resmetirom Priority Review and Breakthrough Therapy designation. The safety profile of resmetirom has been reinforced, and it is under review to become the first medicine approved to treat patients with NASH with liver fibrosis. The publication will provide clinicians with valuable information in treating NASH, a leading cause of liver-related mortality globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
clinical trial
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. announced the granting of equity awards to seven new employees under the 2023 Inducement Plan. The awards include options to purchase 24,538 shares of common stock, time-based restricted stock units, and market-based performance stock units. The options have an exercise price of $222.23 per share and vest over time, while the restricted stock units vest in increments over four years. The MSUs vest upon certification of stock price performance until December 31, 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
none
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announces the addition of three new leaders to its team: Mark Barrett as Chief Business Officer, Clint Wallace as Chief Human Resources Officer, and Tina Ventura as Chief Investor Relations Officer. These leaders bring extensive experience in biopharmaceuticals, human resources, and investor relations. The company is preparing for a first-to-market launch of resmetirom in NASH with significant fibrosis, focusing on enduring leadership and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
management
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. announced the granting of equity awards to 109 new employees under the company's 2023 Inducement Plan. The employees received options to purchase 14,206 shares of Madrigal’s common stock and 32,788 time-based restricted stock units. The options have an exercise price of $243.92 per share and vest over time, while the restricted stock units vest in increments over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) presented five health economics abstracts at the NASH-TAG Conference, highlighting the serious clinical burden of uncontrolled NASH and identifying opportunities to improve patient care. An analysis of patient records from a large claims database revealed that the risk of progressing to cirrhosis, decompensated cirrhosis, liver transplant, or all-cause death increased from 10.5% after one year to 31.4% after 5 years in patients with noncirrhotic NASH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (MDGL) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
conferences
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) granted equity awards to thirty-two new employees as part of the company's 2023 Inducement Plan, involving 10,571 time-based restricted stock units vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (MDGL) granted equity awards to its new Chief Commercial Officer and twelve other new employees under the 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). Carole Huntsman received options to purchase 10,077 shares of Madrigal’s common stock and 7,834 time-based restricted stock units. The other new employees received options to purchase 5,441 shares of Madrigal’s common stock and 11,397 time-based restricted stock units. All options have an exercise price of $190.05 per share and vest over time, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
none
-
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (MDGL) appoints Ronald Filippo as Chief Information Officer, leveraging his 25 years of digital experience in the biopharmaceutical industry. The move reflects the company's commitment to enhancing business operations with AI and digital technologies as they prepare for the launch of resmetirom, a first-to-market product for NASH patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
management
Rhea-AI Summary
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced the granting of equity awards to 18 new employees as inducement for their acceptance of employment. The awards include 28,246 restricted stock units and stock options to acquire 10,385 shares of common stock, subject to vesting conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
none
Madrigal Pharmaceuticals Inc

Nasdaq:MDGL

MDGL Rankings

MDGL Stock Data

4.54B
12.05M
9.73%
100.13%
15.92%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Fort Washington

About MDGL

madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.